Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast Cancer

Video

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

It is not well known whether hormone-directed strategies could be a relevant strategy in treating patients with TNBC, says Page. There are some data that suggest that in about half of patients with TNBC, the expression of androgen receptor is upregulated and could be relevant in the signaling process. Early data have shown that physicians can block androgens.

Page states that there is provocative evidence that physicians can stimulate immune responses and generate new T cells because the thymus, an organ that sits within the chest, is dependent on androgen signaling. If physicians can block that signaling, they may be able to stimulate the production of new T cells, says Page. This is currently being investigated in ongoing clinical trials.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD